123 related articles for article (PubMed ID: 34513918)
1. Molecular and Clinical Characterization of LIGHT/TNFSF14 Expression at Transcriptional Level
Yang Y; Lv W; Xu S; Shi F; Shan A; Wang J
Front Mol Biosci; 2021; 8():567327. PubMed ID: 34513918
[TBL] [Abstract][Full Text] [Related]
2. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
Wang Z; Zhang C; Liu X; Wang Z; Sun L; Li G; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Oncoimmunology; 2016; 5(11):e1196310. PubMed ID: 27999734
[No Abstract] [Full Text] [Related]
3. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
Wang J; Shi F; Shan A
Front Oncol; 2022; 12():946967. PubMed ID: 36276141
[TBL] [Abstract][Full Text] [Related]
4. Molecular and clinical characterization of ANG expression in gliomas and its association with tumor-related immune response.
Wang J; Shan A; Shi F; Zheng Q
Front Med (Lausanne); 2023; 10():1044402. PubMed ID: 37928479
[TBL] [Abstract][Full Text] [Related]
5. Uridine phosphorylase 1 is a novel immune-related target and predicts worse survival in brain glioma.
Wang J; Xu S; Lv W; Shi F; Mei S; Shan A; Xu J; Yang Y
Cancer Med; 2020 Aug; 9(16):5940-5947. PubMed ID: 32583596
[TBL] [Abstract][Full Text] [Related]
6. Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma.
Zhang C; Zhang Z; Li F; Shen Z; Qiao Y; Li L; Liu S; Song M; Zhao X; Ren F; He Q; Yang B; Fan R; Zhang Y
Oncoimmunology; 2018; 7(11):e1461304. PubMed ID: 30377558
[No Abstract] [Full Text] [Related]
7. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
8. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
9. BDKRB2 is a novel EMT-related biomarker and predicts poor survival in glioma.
Yang Y; Wang J; Shi F; Shan A; Xu S; Lv W
Aging (Albany NY); 2021 Mar; 13(5):7499-7516. PubMed ID: 33686021
[TBL] [Abstract][Full Text] [Related]
10.
Yang Y; Wang J; Xu S; Lv W; Shi F; Shan A
Transl Neurosci; 2021 Jan; 12(1):9-19. PubMed ID: 33552590
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical characterization of TMEM71 expression at the transcriptional level in glioma.
Wang KY; Huang RY; Tong XZ; Zhang KN; Liu YW; Zeng F; Hu HM; Jiang T
CNS Neurosci Ther; 2019 Sep; 25(9):965-975. PubMed ID: 31180187
[TBL] [Abstract][Full Text] [Related]
12. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
Long S; Li M; Liu J; Yang Y; Li G
Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
[TBL] [Abstract][Full Text] [Related]
13. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.
Li G; Wang Z; Zhang C; Liu X; Cai J; Wang Z; Hu H; Wu F; Bao Z; Liu Y; Zhao L; Liang T; Yang F; Huang R; Zhang W; Jiang T
Oncoimmunology; 2017; 6(8):e1328339. PubMed ID: 28919992
[No Abstract] [Full Text] [Related]
14. Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas.
Han M; Sun Y; Zhao W; Xiang G; Wang X; Jiang Z; Xue Z; Zhou W
Front Immunol; 2022; 13():1025286. PubMed ID: 36341396
[TBL] [Abstract][Full Text] [Related]
15. Immune and Clinical Features of
Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F
Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Liu S; Zhang C; Maimela NR; Yang L; Zhang Z; Ping Y; Huang L; Zhang Y
Oncoimmunology; 2019; 8(7):1601478. PubMed ID: 31143523
[TBL] [Abstract][Full Text] [Related]
17. Clinical Characterization and Prognostic Value of TPM4 and Its Correlation with Epithelial-Mesenchymal Transition in Glioma.
Wang J; Yang Y; Du B
Brain Sci; 2022 Aug; 12(9):. PubMed ID: 36138856
[TBL] [Abstract][Full Text] [Related]
18. Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma.
Yuan Y; Zhao Q; Zhao S; Zhang P; Zhao H; Li Z; Du Y; Tian X; Lu J
Cancer Med; 2019 Jul; 8(8):3811-3821. PubMed ID: 31140757
[TBL] [Abstract][Full Text] [Related]
19. Calumenin contributes to epithelial-mesenchymal transition and predicts poor survival in glioma.
Yang Y; Wang J; Xu S; Shi F; Shan A
Transl Neurosci; 2021 Jan; 12(1):67-75. PubMed ID: 33623713
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients.
Liu C; Zhang Z; Ping Y; Qin G; Zhang K; Maimela NR; Huang L; Yang S; Zhang Y
Cancer Manag Res; 2020; 12():4399-4410. PubMed ID: 32606935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
